The Cost of Diabetes Care—An Elephant in the Room

Everyone dealing with health care today knows there is an elephant in the room, impossible to miss but frequently ignored—the cost of diabetes care. Although clinicians and scientists may wish to neglect the financial side of diabetes care and focus on less contentious and more familiar matters, this option is no longer viable. For people with diabetes and their families, the elephant stands in the way every day, and for those who plan health services and payment, it is a major concern. Fortunately, the scientific methods used in epidemiologic, clinical, and health services research can be applied to the economics of diabetes care. Collecting observations, identifying patterns, forming hypotheses, and prospectively testing the hypotheses can be just as relevant when one of the variables examined is the cost of care. It is the mission of Diabetes Care to present the best scientific studies related to diabetes. This issue of Diabetes Care has a special section focused on the economic impact of diabetes, including studies designed to understand it and to assess potential solutions. The American Diabetes Association (ADA) has previously reported the costs of diabetes in the U.S. for the years 2002 (1), 2007 (2), and 2012 (3). This issue of Diabetes Care includes a 2017 update (4). Because the methods used in these analyses are similar, comparisons are possible. The most noteworthy findings from the current report are the continuing increase and the remarkable magnitude of the total direct costs of diabetes in the U.S.: $116 billion in 2007, $176 billion in 2012, and $237 billion in 2017. The cost of care for people with diabetes now accounts for ∼1 in 4 health care dollars spent in the U.S. Care for a person with diabetes now costs an average of $16,752 per year. As in prior reports, the 2017 …

[1]  S. McGhee,et al.  Five-Year Cost-effectiveness of the Multidisciplinary Risk Assessment and Management Programme–Diabetes Mellitus (RAMP-DM) , 2017, Diabetes Care.

[2]  Ping Zhang,et al.  Economic Costs of Diabetes in the U.S. in 2017 , 2018, Diabetes Care.

[3]  J. Leahy Economic Costs of Diabetes in the U.S. in 2007 , 2008 .

[4]  Plamen Nikolov,et al.  Economic Costs of Diabetes in the U.S. in 2002 , 2003, Diabetes care.

[5]  R. Holle,et al.  Health Care Costs Associated With Incident Complications in Patients With Type 2 Diabetes in Germany , 2018, Diabetes Care.

[6]  E. Wan,et al.  Five-Year Effectiveness of the Multidisciplinary Risk Assessment and Management Programme–Diabetes Mellitus (RAMP-DM) on Diabetes-Related Complications and Health Service Uses—A Population-Based and Propensity-Matched Cohort Study , 2017, Diabetes Care.

[7]  Christine Y. Lu,et al.  Effect of High-Deductible Insurance on High-Acuity Outcomes in Diabetes: A Natural Experiment for Translation in Diabetes (NEXT-D) Study , 2018, Diabetes Care.

[8]  D. Magliano,et al.  The Productivity Burden of Diabetes at a Population Level , 2018, Diabetes Care.

[9]  E. Gregg The Changing Tides of the Type 2 Diabetes Epidemic—Smooth Sailing or Troubled Waters Ahead? Kelly West Award Lecture 2016 , 2017, Diabetes Care.

[10]  D. Marrero,et al.  Impact of the 2013 National Rollout of CMS Competitive Bidding Program: The Disruption Continues , 2017, Diabetes Care.

[11]  E. Luman,et al.  A National Effort to Prevent Type 2 Diabetes: Participant-Level Evaluation of CDC’s National Diabetes Prevention Program , 2017, Diabetes Care.

[12]  D. Marrero,et al.  Impact of CMS Competitive Bidding Program on Medicare Beneficiary Safety and Access to Diabetes Testing Supplies: A Retrospective, Longitudinal Analysis , 2016, Diabetes Care.

[13]  Ping Zhang,et al.  The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention , 2012, Diabetes Care.

[14]  Seth A. Berkowitz,et al.  Unstable Housing and Diabetes-Related Emergency Department Visits and Hospitalization: A Nationally Representative Study of Safety-Net Clinic Patients , 2018, Diabetes Care.

[15]  J. Gallivan,et al.  The National Diabetes Education Program at 20 Years: Lessons Learned and Plans for the Future , 2018, Diabetes Care.

[16]  Joshua T. Cohen,et al.  Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. , 2014, The New England journal of medicine.

[17]  E. Barrett-Connor,et al.  Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation , 2017, Diabetes Care.

[18]  The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 2012;35:723–730 , 2013, Diabetes Care.

[19]  Kanaka D. Shetty,et al.  Economic Evaluation of Quality Improvement Interventions Designed to Improve Glycemic Control in Diabetes: A Systematic Review and Weighted Regression Analysis , 2018, Diabetes Care.

[20]  W. Herman,et al.  Changes in Health Insurance Coverage Under the Affordable Care Act: A National Sample of U.S. Adults With Diabetes, 2009 and 2016 , 2018, Diabetes Care.

[21]  Mohammed K. Ali,et al.  Declines in the Incidence of Diabetes in the U.S.—Real Progress or Artifact? , 2017, Diabetes Care.

[22]  Till Bärnighausen,et al.  Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030 , 2018, Diabetes Care.

[23]  K. Nasir,et al.  Trends in Diabetes-Related Preventable Hospitalizations in the U.S., 2005–2014 , 2018, Diabetes Care.